Related Experiment Video
Updated: Sep 17, 2026

The Application Of Permanent Middle Cerebral Artery Ligation in the Mouse
Published on: July 25, 2011
Lupus anticoagulants, anticardiolipin antibodies, and cerebral ischemia
1Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia 19104.
Insights
This study found that patients with cerebral ischemia and antiphospholipid antibodies, such as lupus anticoagulant (LA) and anticardiolipin antibodies (ACA), often experience recurrent strokes. Laboratory test results for LA and ACA can be inconsistent, highlighting diagnostic challenges.
Area of Science:
- Neurology
- Rheumatology
- Immunology
Background:
- Cerebral ischemia is a significant cause of neurological disability.
- Antiphospholipid antibodies, including lupus anticoagulant (LA) and anticardiolipin antibodies (ACA), are associated with an increased risk of thrombosis.
- The role of these antibodies in patients with cerebral ischemia requires further elucidation.
Purpose of the Study:
- To investigate the prevalence and clinical characteristics of cerebral ischemia in patients with laboratory evidence of lupus anticoagulant (LA) or anticardiolipin antibodies (ACA).
- To assess the association between these antibodies and cerebrovascular events.
- To evaluate the heterogeneity of laboratory findings in this patient cohort.
Main Methods:
- Retrospective analysis of 23 patients with cerebral ischemia and positive laboratory tests for LA or ACA.
- Clinical data collection including medical history, neurological examination, and presence of collagen-vascular disease.
- Laboratory testing for LA and ACA, including assessment of partial thromboplastin time.
Main Results:
- 71% of patients experienced multiple cerebral ischemic events; two had multi-infarct dementia.
- 57% of patients had recognized cerebrovascular disease risk factors.
- LA was identified in 15/21 patients, and elevated ACA titer in 10/12 patients; assays were discordant in 8/10.
- Only 35% of patients had a prolonged partial thromboplastin time.
Conclusions:
- Cerebral ischemia associated with LA and ACA is often recurrent.
- Other cerebrovascular disease risk factors are frequently present in these patients.
- Significant heterogeneity exists in laboratory findings for LA and ACA, posing diagnostic challenges.
Abstract:
We studied 23 patients suffering cerebral ischemia who also had laboratory evidence of either a lupus anticoagulant (LA) or an abnormal anticardiolipin antibody (ACA). Four patients had lupus or a lupus-like illness, three had drug-induced lupus, and 16 had no overt evidence of collagen-vascular disease. Cerebral ischemic events were multiple in 71% of the patients; two patients presented with multi-infarct dementia. Recognized cerebrovascular disease risk factors were present in 57% of the patients. The partial thromboplastin time was prolonged in only 35% of the patients. An LA was identified in 15 of 21 patients tested, and an elevated ACA titer was identified in 10 of 12 patients tested. Simultaneous assays for LA and ACA were discordant in eight of 10 patients tested. LA- and ACA-associated brain ischemia is often recurrent, but other risk factors for cerebrovascular disease are often present. The laboratory findings in such patients may display considerable heterogeneity.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Ischemic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction
Transient Ischemic Attack l: Introduction

